

<http://www.pjbs.org>

**PJBS**

ISSN 1028-8880

**Pakistan  
Journal of Biological Sciences**

**ANSI***net*

Asian Network for Scientific Information  
308 Lasani Town, Sargodha Road, Faisalabad - Pakistan

## Subclinical Hypothyroidism Effects on Cardiac Function

<sup>1</sup>M. Niafar, <sup>2</sup>M. Toufan, <sup>3</sup>S. Ghafoori and <sup>1</sup>N. Aghamohammadzadeh

<sup>1</sup>Endocrinology and Metabolism Section, Department of Medicine, Imam Reza Hospital,  
Tabriz University of Medical Sciences, Tabriz, Iran

<sup>2</sup>Cardiology Section, Department of Medicine, Madani Hospital,  
Tabriz University of Medical Sciences, Tabriz, Iran

<sup>3</sup>Resident of Internal Medicine, Department of Internal Medicine, Imam Reza Hospital,  
Tabriz University of Medical Sciences, Tabriz, Iran

**Abstract:** To evaluate heart function in subclinical hypothyroid women in comparison with healthy subjects, a prospective study was performed on newly detected subclinical hypothyroid women presenting to endocrinology clinic of Tabriz Sina Hospital from October 2007 to February 2008. Thirty five women with Subclinical Hypothyroidism (SH) in case group were matched with 35 healthy euthyroid women in control group. All patients in both groups were studied by two dimensional echocardiography and Tissue Doppler Imaging (TDI) in Tabriz Shahid Madani Hospital. The FT4 and TSH levels were measured. Comparison of TDI results in Right Ventricle (RV) showed the significantly lower mean  $T_e$  excursion in case group with no significant difference in other parameters. In Left Ventricle (LV), the mean  $A_m$ ,  $A_v$  and  $E_v/E_m$  were significantly higher and  $E/A$  was lower in the case group, but there was no significant difference in other parameters. No RV diastolic dysfunction was documented in both groups. There was no case with LV systolic dysfunction in both groups. There were 21 (60%) patients with LV diastolic dysfunction in the case group comparing with 11 (31.4%) cases in the control group ( $p = 0.016$ , OR = 0.306). Frequency of LV diastolic dysfunction was significantly higher in the case group in patients aged  $\geq 40$  years (94.1% vs. 53.3%;  $p = 0.013$ ). There was no case of pericardial effusion in the studied population. According to our results, SH may cause LV diastolic dysfunction. Likewise, minor RV systolic dysfunction might be seen in these patients.

**Key words:** Subclinical hypothyroidism, tissue doppler imaging, diastolic dysfunction

### INTRODUCTION

There is biological plausibility to the premise that subclinical thyroid dysfunction may cause adverse cardiac consequences (Cappola, 2007). Multiple studies have examined the relationships between endogenous SH (Dorr *et al.*, 2005; Owen *et al.*, 2006; Franzoni *et al.*, 2006; Aghini-Lombardi *et al.*, 2006; Kosar *et al.*, 2005; Turhan *et al.*, 2006) and echocardiographic measures of systolic and diastolic function (Cappola, 2007). SH can have repercussions on the cardiovascular system, as well as on other organs and systems (Biondi and Cooper, 2008).

Subclinical Hypothyroidism (SH) is an apparently asymptomatic condition defined by slightly increased serum Thyroid-Stimulating Hormone (TSH) concentrations and normal free thyroid hormone levels. As reported, in iodine sufficient areas, SH occurs in 4-9.5% of the general population, being more frequent in women and in the elderly (Aghini-Lombardi *et al.*, 2006;

Duarte *et al.*, 2009; Ochs *et al.*, 2008; Papi *et al.*, 2007; Surks *et al.*, 2004). In view of the minimal hormonal impairment and the apparent failure of symptoms, the need of a life-long treatment with levothyroxine (L-T<sub>4</sub>) is a matter of controversy. Nevertheless, this condition may be clinically relevant at level of target organs over a period of several years. Cardiovascular system is very sensitive to minimal defects of circulating thyroid hormones and cardiovascular disorders are usually associated with overt hypothyroidism (Kahaly and Dillmann, 2005). Furthermore, the abnormalities in myocardial contractility and the changes of the lipoprotein profile that are frequently documented in hypothyroid patients have been reported by Kahaly and Dillmann (2005) and Sahin *et al.* (2005). Therefore, SH may be considered a true risk factor for the development of coronary heart disease (Kahaly and Dillmann, 2005; Fazio *et al.*, 2004). Indeed, a progression of coronary angiographic lesions in untreated SH patients in

comparison with L-T<sub>4</sub>-treated SH patients has been reported (Kahaly and Dillmann, 2005; Sahin *et al.*, 2005; Fazio *et al.*, 2004). Recently, it has been reported by an ultrasonic tissue characterization technique (videodensitometry) that SH is associated with early abnormalities in both myocardial function and structure, which are reversible with replacement therapy (Aghini-Lombardi *et al.*, 2006). However, there has been heterogeneity in studies of SH. Two studies have shown no difference in left ventricular mass or function between individuals with and without SH (Dorr *et al.*, 2005; Owen *et al.*, 2006) and of the remaining studies that have detected systolic and/or diastolic abnormalities using echocardiography, no pair of these studies report the same pattern of abnormal parameters (Franzoni *et al.*, 2006; Aghini-Lombardi *et al.*, 2006; Kosar *et al.*, 2005; Turhan *et al.*, 2006; Vitale *et al.*, 2002).

The aim of the present study was to evaluate heart function in subclinical hypothyroid women, in comparison with healthy subjects by conventional echocardiography and Tissue Doppler Imaging (TDI).

## MATERIALS AND METHODS

The study was prospective performed on newly detected subclinical hypothyroid women presenting to endocrinology clinic of Tabriz Sina Hospital from October 2007 to February 2008. According to the earlier studies and using  $N = Z^2pq/d^2$  formulation ( $Z^2 = 3.84$ ,  $p = 0.1$ ,  $q = 0.9$ ), the required sample size was calculated as 35 (Ariola *et al.*, 2006; Wayne and Terrell, 1986). Thirty five women with Subclinical Hypothyroidism (SH) in case group were matched with 35 healthy euthyroid women in control group. Exclusion criteria were use of thyroid or other hormonal drugs, antihypertensive agents, congenital or acquired heart disease and pregnancy. Patients and normal control subjects were enrolled consecutively to make number, BMI and age become the same in both groups. Written informed consent was obtained from each patient. All patients in case and control groups were studied by two dimensional echocardiography and tissue Doppler imaging in Tabriz Shahid Madani Hospital.

The patients parameters were recorded including age, BMI, systolic and diastolic blood pressure, heart rate, free thyroxine (FT4) and thyrotropin and pleural effusion (if any). The right ventricle parameters measured by TDI and 2D echocardiography were as following: Ev/Em, Ev, E/A, Em, Av, EDECT, Am, Sm, TvE, TPC, RVDD, RVSP, TRg, TRv and RV systolic and diastolic function. The left ventricle parameters measured by TDI and two dimensional echocardiography were as following: Ev/Em,

Ev, E/A, Em, Av, EDECT, Am, Sm, EF, LVMI, LVDD, LVSD, LAD, TPC and LV systolic and diastolic function. The echocardiographic parameters in tow groups of <40 years and ≥40 years were compared with each other. Immediately after rapid centrifugation of a blood sample collected at 7 AM from an antecubital vein, FT4 and TSH levels were measured (Singh *et al.*, 2008; Rodondi *et al.*, 2008; Zoncu *et al.*, 2005).

Echocardiography was performed for all cases and control subjects by one subspecialist. The echocardiologist was unaware about the thyroid function status of studied person. Transthoracic echocardiography (TTE), was performed by Vivid7<sup>®</sup>USA echocardiography machine, using 3.5MHz prob. The achieved graphs were recorded in standard parasternal long axis and apical views, by following methods: M-mode, 2D echo, color Doppler and Tissue Doppler Imaging (TDI). Ejection Fraction (EF) was calculated by both M-mode and eyeball methods. The LV mass index was calculated by both M-mode using following formulation:

$$LV \text{ mass} = 0.8[(IVSD+LVDD+PWT)^2 - (LVDD)^2] + 0.6(g)$$

(Singh *et al.*, 2008; Rodondi *et al.*, 2008; Zoncu *et al.*, 2005).

The LV diastolic function was assessed by tissue Doppler method in base lateral wall of LV. The RV assessments were performed in four chamber view as measurement of RV size and evaluation of TV excursion for determination of RV longitudinal contraction during systole. The TDI method was used for evaluation of motion speed of myocardial muscle of RV free wall during systole and diastole. The collected data were analyzed by SPSS-15 statistical software using the following methods: student t-test (independent samples) for comparison of quantitative variables, Chi-square test or Fishers Exact test for comparison of qualitative (categorical) variables. The  $p = 0.05$  were considered significant (Singh *et al.*, 2008; Rodondi *et al.*, 2008; Zoncu *et al.*, 2005).

## RESULTS

Thirty five subclinical hypothyroid women (case group) with average age of  $38.89 \pm 11.32$  year were compared with 35 normal healthy women (control group) with average age of  $40.43 \pm 10.75$  year ( $p = 0.838$ ). The women with age <40 year was 18 (51.4%) in case and 20 (57.1%) in control group. The women with age ≥40 year was 17 (48.6%) in case and 15 (42.9%) in control group.

Average BMI was  $26.32 \pm 4.78$  kg m<sup>-2</sup> in case and  $26.84 \pm 4.73$  kg m<sup>-2</sup> in control group ( $p = 0.648$ ). Average Systolic Blood Pressure (SBP) was  $115.40 \pm 11.99$  mmHg in

**Table 1: Echocardiographic parameters of right and left ventricles in case and control groups**

Right ventricle				Left ventricle			
Variables	Group	Average	p-value	Variables	Group	Average	p-value
E <sub>v</sub> /E <sub>m</sub>	Case	4.36±1.89	0.184	E <sub>v</sub> /E <sub>m</sub>	Case	6.60±2.43	0.049
	Control	3.87±1.02			Control	5.63±1.53	
E <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.58±0.10	0.706	E <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.85±0.14	0.884
	Control	0.57±0.10			Control	0.85±0.13	
E/A	Case	1.21±0.24	0.162	E/A	Case	1.23±0.34	0.168
	Control	1.31±0.32			Control	1.35±0.38	
E <sub>m</sub> (cm sec <sup>-1</sup> )	Case	14.77±4.77	0.561	E <sub>m</sub> (cm sec <sup>-1</sup> )	Case	14.37±5.24	0.286
	Control	15.37±3.77			Control	15.57±4.02	
A <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.49±0.10	0.198	A <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.72±0.16	0.136
	Control	0.46±0.11			Control	0.67±0.14	
E <sub>DECT</sub> (m sec)	Case	240.39±83.12	0.287	E <sub>DECT</sub> (m sec)	Case	213.86±44.59	0.751
	Control	260.69±75.08			Control	217.24±44.08	
A <sub>m</sub> (cm sec <sup>-1</sup> )	Case	14.23±4.50	0.122	A <sub>m</sub> (cm sec <sup>-1</sup> )	Case	11.00±3.63	0.114
	Control	16.06±5.24			Control	9.77±2.72	
S <sub>m</sub> (cm sec <sup>-1</sup> )	Case	15.20±3.29	0.314	S <sub>m</sub> (cm sec <sup>-1</sup> )	Case	11.31±2.97	0.928
	Control	14.51±2.28			Control	11.26±2.27	
T <sub>v</sub> E (cm)	Case	2.10±0.23	0.047	MAE (cm)	Case	1.49±0.27	0.273
	Control	2.24±0.33			Control	1.56±0.23	
TPC (m sec)	Case	148.89±28.38	0.569	TPC (m sec)	Case	115.22±30.00	0.792
	Control	152.91±30.17			Control	113.16±35.05	
RVDD (cm)	Case	2.84±0.36	0.480	EF (%)	Case	58.43±2.36	0.803
	Control	2.90±0.29			Control	58.29±2.41	
RVSP (mmHg)	Case	26.83±5.00	0.704	LVMI (g m <sup>-2</sup> )	Case	82.25±19.63	0.144
	Control	27.26±4.19			Control	75.95±15.81	
TR <sub>q</sub> (mmHg)	Case	17.14±4.65	0.781	LVDD (cm)	Case	4.33±0.34	0.336
	Control	17.44±4.23			Control	4.25±0.39	
TR <sub>w</sub> (m sec <sup>-1</sup> )	Case	2.09±0.26	0.991	LVSD (cm)	Case	2.93±0.32	0.084
	Control	2.08±0.26			Control	2.79±0.34	
				LAD (cm)	Case	3.27±0.47	0.552
				Control	3.21±0.42		

case and 113/37±9.43 mmHg in control group (p = 0.434). Average Diastolic Blood Pressure (DBP) was 75.34±10.47 mmHg in case and 70.34±8.38 (mmHg) in control group. Average DBP was significantly higher in case group (p = 0.031).

Average Heart Rate (HR) was 81.89±10.04 bpm in case and 76.54±11.47 bpm in control group. Average HR was significantly higher in case group (p = 0.042). In case group, the average serum TSH was 11.68±4.37 mg L<sup>-1</sup> and the average serum FT4 was 1.09±0.21 µg dL<sup>-1</sup>. Table 1 shows the average echocardiographic parameters of right and left ventricles in case and control groups. As showed in Table 1, T<sub>v</sub> excursion in right ventricle was significantly less in case group. Also, E<sub>v</sub>/E<sub>m</sub> in left ventricle was significantly more in case group. Other echocardiographic parameters of right and left ventricles were not significantly different in case and control groups. There was not pericardial effusion in case or control groups.

There was not any case of RV diastolic dysfunction and LV systolic dysfunction in case or control groups. However, there were 21 women with LV diastolic dysfunction in case group and 11 women with LV diastolic dysfunction grade I in control group. The LV diastolic dysfunction was significantly more in case group (p = 0.016, 95% CI :0.11-0.82, OR = 0.306).

Table 2 shows the average echocardiographic parameters of right and left ventricles in women aged <40 years in case and control groups. As showed in Table 2, echocardiographic parameters of right and left ventricles in this age range were not significantly different between two groups. There were 5 women with LV diastolic dysfunction in case group and 3 women with LV diastolic dysfunction in control group. LV diastolic dysfunction in women aged <40 years was not significantly different (p = 0.438, 95% CI: 0.09-2.28, OR = 0.459).

Table 3 shows the average echocardiographic parameters of right and left ventricles in women aged ≥40 years in case and control groups. As showed in Table 3, echocardiographic parameters of right ventricle in this age range were not significantly different between two groups. In left ventricle of women aged ≥40, the average A<sub>m</sub>, A<sub>v</sub> and E<sub>v</sub>/E<sub>m</sub> were significantly higher and the average E/A was significantly less in case group. There were 16 women with LV diastolic dysfunction grade I in case group and 8 women with same LV diastolic dysfunction in control group. The LV diastolic dysfunction in women aged ≥40 years was significantly more in case group (p = 0.013, 95% CI: 0.01-0.69, OR = 0.071).

**Table 2: Echocardiographic parameters of right and left ventricles in women aged <40 years in case and control groups**

Right ventricle				Left ventricle			
Variables	Group	Average	p-value	Variables	Group	Average	p-value
E <sub>v</sub> /E <sub>m</sub>	Case	3.74±1.23	0.604	E <sub>v</sub> /E <sub>m</sub>	Case	5.05±0.84	0.955
	Control	3.94±1.05			Control	5.07±1.33	
E <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.58±0.10	0.887	E <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.88±0.13	0.771
	Control	0.59±0.11			Control	0.89±0.09	
E/A	Case	1.28±0.25	0.359	E/A	Case	1.46±0.27	0.732
	Control	1.36±0.30			Control	1.42±0.35	
E <sub>m</sub> (cm sec <sup>-1</sup> )	Case	16.33±3.43	0.616	E <sub>m</sub> (cm sec <sup>-1</sup> )	Case	17.83±4.08	0.787
	Control	15.70±4.19			Control	17.50±3.47	
A <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.47±0.09	0.422	A <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.61±0.09	0.266
	Control	0.44±0.10			Control	0.65±0.13	
E <sub>DECT</sub> (m sec)	Case	219.70±91.19	0.117	E <sub>DECT</sub> (m sec)	Case	204.54±36.15	0.462
	Control	264.17±79.54			Control	214.20±43.17	
A <sub>m</sub> (cm sec <sup>-1</sup> )	Case	12.17±3.55	0.114	A <sub>m</sub> (cm sec <sup>-1</sup> )	Case	8.72±2.35	0.359
	Control	14.50±5.09			Control	9.55±3.05	
S <sub>m</sub> (cm sec <sup>-1</sup> )	Case	15.22±2.69	0.539	S <sub>m</sub> (cm sec <sup>-1</sup> )	Case	12.39±2.97	0.640
	Control	14.70±2.49			Control	12.00±2.08	
T <sub>v</sub> E (cm)	Case	2.10±0.26	0.137	MAE (cm)	Case	1.46±0.23	0.058
	Control	2.25±0.34			Control	1.61±0.24	
TPC (m sec)	Case	157.50±26.72	0.754	TPC (m sec)	Case	109.24±24.48	0.847
	Control	160.28±27.43			Control	107.41±32.69	
RVDD (cm)	Case	2.90±0.33	0.609	EF (%)	Case	59.17±1.92	0.892
	Control	2.95±0.24			Control	59.25±1.83	
RVSP (mmHg)	Case	25.31±4.46	0.448	LVMI (g m <sup>-2</sup> )	Case	77.25±12.59	0.564
	Control	26.44±4.39			Control	74.42±16.79	
TR <sub>q</sub> (mmHg)	Case	15.34±4.64	0.324	LVDD (cm)	Case	4.37±0.29	0.619
	Control	16.81±4.44			Control	4.32±0.37	
TR <sub>w</sub> (m sec <sup>-1</sup> )	Case	2.04±0.22	0.945	LVSD (cm)	Case	2.97±0.26	0.121
	Control	2.05±0.28			Control	2.83±0.30	
				LAD (cm)	Case	3.16±0.50	0.930
				Control	3.14±0.48		

**Table 3: Echocardiographic parameters of right and left ventricles in women aged ≥40 years in case and control groups**

Right ventricle				Left ventricle			
Variables	Group	Average	p-value	Variables	Group	Average	p-value
E <sub>v</sub> /E <sub>m</sub>	Case	5.01±2.26	0.063	E <sub>v</sub> /E <sub>m</sub>	Case	8.25±2.50	0.017
	Control	3.78±1.02			Control	6.38±1.50	
E <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.57±0.11	0.402	E <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.82±0.16	0.857
	Control	0.54±0.08			Control	0.81±0.17	
E/A	Case	1.14±0.20	0.379	E/A	Case	0.99±0.21	0.025
	Control	1.23±0.33			Control	1.25±0.40	
E <sub>m</sub> (cm sec <sup>-1</sup> )	Case	13.12±5.49	0.271	E <sub>m</sub> (cm sec <sup>-1</sup> )	Case	10.71±3.58	0.069
	Control	14.93±3.22			Control	13.00±3.25	
A <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.51±0.11	0.368	A <sub>v</sub> (m sec <sup>-1</sup> )	Case	0.84±0.14	0.006
	Control	0.47±0.11			Control	0.69±0.15	
E <sub>DECT</sub> (m sec)	Case	262.31±69.67	0.804	E <sub>DECT</sub> (m sec)	Case	223.73±51.33	0.889
	Control	256.05±71.15			Control	221.29±46.46	
A <sub>m</sub> (cm sec <sup>-1</sup> )	Case	16.41±4.44	0.303	A <sub>m</sub> (cm sec <sup>-1</sup> )	Case	13.41±3.18	0.002
	Control	18.13±4.84			Control	10.07±2.28	
S <sub>m</sub> (cm sec <sup>-1</sup> )	Case	15.18±3.91	0.424	S <sub>m</sub> (cm sec <sup>-1</sup> )	Case	10.18±2.58	0.916
	Control	14.27±2.02			Control	10.27±2.19	
T <sub>v</sub> E (cm)	Case	2.11±0.21	0.214	MAE (cm)	Case	1.53±0.32	0.703
	Control	2.23±0.32			Control	1.49±0.20	
TPC (m sec)	Case	139.78±27.96	0.757	TPC (m sec)	Case	121.55±34.53	0.955
	Control	143.07±31.74			Control	120.83±37.72	
RVDD (cm)	Case	2.78±0.40	0.708	EF (%)	Case	57.65±2.57	0.480
	Control	2.83±0.34			Control	57.00±2.54	
RVSP (mmHg)	Case	28.44±5.16	0.903	LVMI (g m <sup>-2</sup> )	Case	87.54±24.34	0.196
	Control	28.24±3.85			Control	77.98±14.71	
TR <sub>q</sub> (mmHg)	Case	19.05±3.93	0.580	LVDD (cm)	Case	4.29±0.39	0.342
	Control	18.27±3.93			Control	4.15±0.41	
TR <sub>w</sub> (m sec <sup>-1</sup> )	Case	2.13±0.30	0.955	LVSD (cm)	Case	2.89±0.39	0.309
	Control	2.14±0.23			Control	2.75±0.39	
				LAD (cm)	Case	3.39±0.41	0.457
				Control	3.29±0.31		

## DISCUSSION

Subclinical Hypothyroidism (SH), defined by elevated serum levels of Thyroid Stimulating Hormone (TSH) with normal levels of free thyroid hormones, belongs to the most common disorders encountered in an endocrine office practice. It is assumed that elevated TSH levels in patients with SH do not reflect pituitary compensation to maintain euthyroidism but probably represents SH (Krysiak *et al.*, 2008; Rodondi *et al.*, 2008). The cardiovascular signs and symptoms of thyroid disease are some of the most profound and clinically relevant findings that accompany hypothyroidism. On the basis of the understanding of the cellular mechanisms of thyroid hormone action on the heart and cardiovascular system, it is possible to explain the changes in cardiac output, cardiac contractility, blood pressure, vascular resistance and rhythm disturbances that result from thyroid dysfunction (Klein and Danzi, 2007).

Iqbal *et al.* (2007) in a case-control study on 66 hypothyroid patients suggest that there are no adverse effects of persistent SH on cardiac function (Cappola, 2007). The mean TSH level of study participants with SH was  $5.4 \text{ mU L}^{-1}$  and their mean age was 61 year. In other studies that included participants with higher mean serum TSH levels and younger age, there were measurable differences in echocardiographic parameters between subclinically hypothyroid and euthyroid subjects (Franzoni *et al.*, 2006; Aghini-Lombardi *et al.*, 2006; Kosar *et al.*, 2005; Turhan *et al.*, 2006). This discrepancy highlights the importance of refining the at risk population and the need to link abnormalities in these surrogate echocardiographic markers with adverse clinical cardiac events, such as congestive heart failure (Cappola, 2007; Rodondi *et al.*, 2005). It is estimated that as many as 7-10% of older women have SH. Although, SH is frequently asymptomatic, many patients have symptoms of thyroid hormone deficiency. Lipid and lipoprotein metabolism is abnormal in SH (Klein and Danzi, 2007; Rodondi *et al.*, 2005; Duntas, 2002; Razvi *et al.*, 2007). C-reactive protein, a risk factor for heart disease, is increased in SH (Christ-Crain *et al.*, 2003). In addition, atherosclerosis (Ochs *et al.*, 2008; Kanaya *et al.*, 2002), coronary heart disease and myocardial infarction risk are increased in women with SH (Klein and Danzi, 2007; Rodondi *et al.*, 2006). The SH should be screened more carefully in the community. There are evidences that treatment of SH is beneficial (Papi *et al.*, 2007; Krysiak *et al.*, 2008; Rodondi *et al.*, 2008). Treatment of SH in pregnant women is mandatory to decrease risks for pregnancy complications and impaired cognitive development in offspring. Children with SH should

be treated to prevent growth retardation. Whether non-pregnant adult patients with SH should be treated (Papi *et al.*, 2007).

In the present study, LV diastolic dysfunction was significantly higher in subclinical hypothyroid women than controls. Yazici *et al.* (2004) study confirms the above-cited findings. Aghini-Lombardi *et al.* (2006) studied 24 subclinical hypothyroid patients in comparison with 24 sex- and age-matched healthy volunteers and found a significant impairment of left ventricular diastolic function in subclinically hypothyroid patients. A study by Vitale *et al.* (2002) on 20 subclinically hypothyroid and 20 healthy women showed cardiac functional abnormalities due to stable SH, mainly by changes in myocardial time intervals in several LV segments. They also found more LV diastolic dysfunction in subclinical hypothyroid patients. Septal myocardium is the most affected region of left ventricle in SH. The relaxation time is the best criteria of cardiac involvement and monitoring the effect of TRT (Arinc *et al.*, 2006). Zoncu *et al.* (2005) showed a delay in diastolic relaxation and a decrease in the compliance to the ventricular filling in subclinically hypothyroid patients. In series of SH patients, the results confirmed the impairment of both systolic and diastolic myocardial function (Di Bello *et al.*, 2000; Monzani *et al.*, 2001), a decreased myocardial intrinsic contractility and a high ultrasonic myocardial reflectivity suggesting an altered myocardial texture. These subtle myocardial alterations were reversible after replacement L-T4 therapy (Aghini-Lombardi *et al.*, 2006; Di Bello *et al.*, 2000). Vitale *et al.* (2002) reported both an impairment of global longitudinal ventricular diastolic function and an alteration of myocardial time intervals, in patients with SH. Zoncu *et al.* (2005) demonstrated systolic and diastolic changes in patients with borderline hypothyroidism. Several studies suggested that SH was associated with a small increased risk for CHD and cardiovascular mortality (Ochs *et al.*, 2008; Rodondi *et al.*, 2008; Iacoviello *et al.*, 2008; Biondi, 2007; Bakiner *et al.*, 2008; Iervasi *et al.*, 2007; Singh *et al.*, 2008). In the present study, LV diastolic dysfunction in women aged  $\geq 40$  years was significantly higher in case group than controls, indicating the importance of early screening of cardiac complications in older ages. An advantage of this study is the use of TDI in evaluation of right ventricle. To date, we did not find such study in this field. The average T<sub>v</sub> Excursion in case group was lower significantly, indicating impaired longitudinal systolic contractility of right ventricle due to SH and presence of mild systolic dysfunction in these patients. Considering the advantage of TDI and its relative independence of load condition and for strain also a relative independence from heart rotational and

translational motions, this technique allows a very early diagnosis of systolic and diastolic dysfunction, when conventional echo-Doppler parameters of left ventricular function are still within normal range (Aghini-Lombardi *et al.*, 2006; Zoncu *et al.*, 2005). It is also an accurate modality to investigate the cardiac effects of SH (Vitale *et al.*, 2002; Arinc *et al.*, 2006).

### CONCLUSION

In summary, our data suggest that subclinical thyroid dysfunction might represent a potentially modifiable risk factor for cardiac dysfunction. Assuming that treatment is effective, given the high prevalence of thyroid disease even a small increase in cardiac morbidity or mortality rates among persons with subclinical dysfunction would have public health implications. From a health policy perspective, it would be premature to recommend screening for thyroid dysfunction in the general population. Given the pattern of modestly increased risk for cardiac morbidity and mortality associated with subclinical thyroid dysfunction, lower risk estimates in higher-quality studies and the remaining uncertainty, treatment of subclinical thyroid dysfunction with cardiac disease as an end point should be studied in randomized, placebo-controlled trials to assess the efficacy of T<sub>4</sub> replacement or anti-thyroid medications before current recommendations are updated. This supports the need for prospective studies aimed at clarifying the most appropriate therapeutic approach to sub-clinical hypothyroidism in such patients.

### REFERENCES

- Aghini-Lombardi, F., V. Di Bello, E. Talini, A. Di Cori and F. Monzani *et al.*, 2006. Early textural and functional alterations of left ventricular myocardium in mild hypothyroidism. *Eur. J. Endocrinol.*, 155: 3-9.
- Arinc, H., H. Gunduz, A. Tamer, E. Seyfeli and M. Kanat *et al.*, 2006. Tissue doppler echocardiography in evaluation of cardiac effects of subclinical hypothyroidism. *Int. J. Cardiovascular Imag.*, 22: 177-186.
- Ariola *et al.*, 2006. Principles and Methods of Research. Rex Bookstore, Inc., USA., pp: 78.
- Bakiner, O., M.E. Ertorer, F.E. Haydardedeoglu, E. Bozkirli and N.B. Tutuncu *et al.*, 2008. Subclinical hypothyroidism is characterized by increased QT interval dispersion among women. *Med. Princ. Pract.*, 17: 390-394.
- Biondi, B., 2007. Cardiovascular effects of mild hypothyroidism. *Thyroid*, 17: 625-630.
- Biondi, B. and D.S. Cooper, 2008. The clinical significance of subclinical thyroid dysfunction. *Endocr. Rev.*, 29: 76-131.
- Cappola, A.R., 2007. Subclinical thyroid dysfunction and the heart. *J. Clin. Endocrinol. Metab.*, 92: 3404-3405.
- Christ-Crain, M., C. Meier, M. Guglielmetti, P.R. Huber and W. Riesen *et al.*, 2003. Elevated C-reactive protein and homocysteine values: Cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind placebo-controlled trial. *Atherosclerosis*, 166: 379-386.
- Di Bello, V., F. Monzani, D. Giorgi, A. Bertini and N. Caraccio *et al.*, 2000. Ultrasonic myocardial textural analysis in subclinical hypothyroidism. *J. Am. Soc. Echocard.*, 13: 832-840.
- Dorr, M., B. Wolff, D.M. Robinson, U. John and J. Ludemann *et al.*, 2005. The association of thyroid function with cardiac mass and left ventricular hypertrophy. *J. Clin. Endocrinol. Metab.*, 90: 673-677.
- Duarte, G.C., E.K. Tomimori, R. Y. Camargo, I.G. Rubio and M. Wajngarten *et al.*, 2009. The prevalence of thyroid dysfunction in elderly cardiology patients with mild excessive iodine intake in the urban area of São Paulo. *Clinics*, 64: 135-142.
- Duntas, L.H., 2002. Thyroid disease and lipids. *Thyroid*, 12: 287-293.
- Fazio, S., E.A. Palmieri, G. Lombardi and B. Biondi, 2004. Effects of thyroid hormone on the cardiovascular system. *Recent Progress Hormone Res.*, 59: 31-50.
- Franzoni, F., F. Galetta, P. Fallahi, L. Tocchini and G. Merico *et al.*, 2006. Effect of L-thyroxine treatment on left ventricular function in subclinical hypothyroidism. *Biomed. Pharmacother*, 60: 431-436.
- Iacoviello, M., P. Guida, E. Guastamacchia, V. Triggiani and C. Forleo *et al.*, 2008. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. *Curr. Pharm. Des.*, 14: 2686-2692.
- Iervasi, G., S. Molinaro, P. Landi, M.C. Taddei and E. Galli *et al.*, 2007. Association between increased mortality and mild thyroid dysfunction in cardiac patients. *Arch. Inter. Med.*, 167: 1526-1532.
- Iqbal, A., H. Schirmer, P. Lunde, Y. Figenschau, K. Rasmussen and R. Jorde, 2007. Thyroid stimulating hormone and left ventricular function. *J. Clin. Endocrinol. Metab.*, 92: 3504-3510.
- Kahaly, G.J. and W.H. Dillmann, 2005. Thyroid hormone action in the heart. *Endocrine Rev.*, 26: 704-728.
- Kanaya, A.M., F. Harris, S. Volpato, E.J. Pérez-Stable, T. Harris and D.C. Bauer, 2002. Association between thyroid dysfunction and total cholesterol level in an older biracial population: The health, aging and body composition study. *Arch Inter. Med.*, 162: 773-779.

- Klein, I. and S. Danzi, 2007. Thyroid disease and the heart. *Circulation*, 116: 1725-1735.
- Kosar, F., I. Sahin, N. Turan, E. Topal and Y. Aksoy *et al.*, 2005. Evaluation of right and left ventricular function using pulsed-wave tissue doppler echocardiography in patients with subclinical hypothyroidism. *J. Endocrinol. Invest.*, 28: 704-710.
- Krysiak, R., B. Marek and B. Okopien, 2008. Subclinical hypothyroidism. *Convul Ther.*, 61: 139-145.
- Monzani, F., V. Di Bello, N. Caraccio, A. Bertini and D. Giorgi *et al.*, 2001. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: A double blind, placebo-controlled study. *J. Clin. Endocrinol. Metabolism*, 86: 1110-1115.
- Ochs, N., R. Auer, D.C. Bauer, D. Nanchen and J. Gusssekloo *et al.*, 2008. Meta-analysis: Subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. *Ann. Int. Med.*, 148: 832-845.
- Owen, P.J., C. Rajiv, D. Vinereanu, T. Mathew and A.G. Fraser *et al.*, 2006. Subclinical hypothyroidism, arterial stiffness and myocardial reserve. *J. Clin. Endocrinol. Metab.*, 91: 2126-2132.
- Papi, G., E.D. Uberti, C. Betterle, C. Carani and E.N. Pearce *et al.*, 2007. Subclinical hypothyroidism. *Curr. Opin. Endocrinol. Diabetes Obes.*, 14: 197-208.
- Razvi, S., L. Ingoe, G. Keeka, C. Oates and C. McMillan *et al.*, 2007. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function and quality of life in subclinical hypothyroidism: Randomised, crossover trial. *J. Clin. Endocrinol. Metab.*, 92: 1715-1723.
- Rodondi, N., A.B. Newman, E. Vittinghoff, N. de Rekeneire and S. Satterfield *et al.*, 2005. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events and death. *Arch. Inter. Med.*, 165: 2460-2466.
- Rodondi, N., D. Aujesky, E. Vittinghoff, J. Cornuz and D.C. Bauer, 2006. Subclinical hypothyroidism and the risk of coronary heart disease: A meta-analysis. *Am. J. Med.*, 119: 541-551.
- Rodondi, N., D.C. Bauer, A.R. Cappola, J. Cornuz and J. Robbins *et al.*, 2008. Subclinical thyroid dysfunction, cardiac function and the risk of heart failure. The Cardiovascular Health study. *J. Am. Coll. Cardiol.*, 52: 1152-1159.
- Sahin, I., N. Turan, F. Kosar, C. Tascapan and H. Gunen, 2005. Evaluation of autonomic activity in patients with subclinical hypothyroidism. *J. Endocrinol. Invest.*, 28: 209-213.
- Singh, S., J. Duggal, J. Molnar, F. Maldonado and C.P. Barsano *et al.*, 2008. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: A meta-analysis. *Int. J. Cardiol.*, 125: 41-48.
- Surks, M.I., E. Ortiz, G.H. Daniels, C.T. Sawin and N.F. Col *et al.*, 2004. Subclinical thyroid disease, scientific review and guidelines for diagnosis and management. *J. Am. Med. Assoc.*, 291: 228-238.
- Turhan, S., C. Tulunay, C.M. Ozduman, A. Gursoy and M. Kilickap *et al.*, 2006. Effects of thyroxine therapy on right ventricular systolic and diastolic function in patients with subclinical hypothyroidism: A study by pulsed wave tissue doppler imaging. *J. Clin. Endocrinol. Metab.*, 91: 3490-3493.
- Vitale, G., M. Galderisi, G.A. Lupoli, A. Celentano and I. Pietropaolo *et al.*, 2002. Left ventricular myocardial impairment in subclinical hypothyroidism assessed by a new ultrasound tool: Pulsed tissue doppler. *J. Clin. Endocrinol. Metab.*, 87: 4350-4355.
- Wayne, W.D. and J.C. Terrell, 1986. *Business Statistics: Basic Concepts and Ethodology*. 4th Edn., Houghton Mifflin Publishers, USA., pp: 153-223.
- Yazici, M., S. Gorgulu, Y. Sertbas, E. Erbilien and S. Albayrak *et al.*, 2004. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: Index of myocardial performance in the evaluation of left ventricular function. *Int. J. Cardiol.*, 95: 135-143.
- Zoncu, S., F. Pigliaru, C. Putzu, L. Pisano and S. Vargiu *et al.*, 2005. Cardiac function in borderline hypothyroidism: A study by pulsed wave tissue doppler imaging. *Eur. J. Endocrinol.*, 152: 527-533.